A pharmacokinetic, pharmacodynamic, and safety study of celecoxib in subjects with probable Alzheimer's disease

Clinical Research and Regulatory Affairs

Volumn 21, Issue 1, 2004, Pages 49-66

  Jhee, Stanford S ^a   Frackiewicz, Edyta J ^a   Tolbert, Dwain ^b   Sainati, Stephen ^b   Karim, Aziz ^b   Zolnouni, Parvaneh P ^a   Choi, Kyung Eob ^c  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b PFIZER INC   (United States)

^c Samsung Medical Center   (South Korea)

Author keywords

Alzheimer's disease; Celecoxib; Cerebrospinal fluid; Double blind study; Randomized

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; INTERLEUKIN 6; PLACEBO; PROSTAGLANDIN E2;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; FEMALE; HEADACHE; HEARING IMPAIRMENT; HUMAN; INFLAMMATION; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; NEUROPHYSIOLOGY; PROSTAGLANDIN SYNTHESIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN DISCOLORATION; TREATMENT OUTCOME;

EID: 3242682654     PISSN: 10601333     EISSN: None     Source Type: Journal    
DOI: 10.1081/CRP-120030034     Document Type: Article

References (29)

1. Aisen PS, Davis KL. Anti-inflammatory theraphy for Alzheimer's disease: a status report. Int J Geriatr Psychopharmacol 1997; 1:2-5.
2. Breitner JC. Inflammatory processes and anti-inflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 1996; 17(5):789-794.
3. Aisenb PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease. Implication for therapy. Am J Psych 1994; 151:1105-1111.
4. Nanderabelle P, Freis W. Is amyloidgenesis during Alzheimer's disease due to an IL-1/IL-6 mediated "acute phase response" on the brain? Immunol Today 1991; 12:217-219.
5. Pasinetti GM. Inflammatory mechanisms in neurodegeration and Alzheimer's disease: the role of the complement system. Microbiol Aging 1996; 17:707-716.
6. Roger J, Luber-Narod J, Styror SD, Civin WN. Expression of immune system-associated antigen by cells of the human nervous system: relationship to the pathology of Alzheimer's disease. Microbiol Aging 1988; 9:330-349.
7. Campbell LL, Abraham CA, Masliah E. Neurologic disease induced in transgenic mice by overexpression of interleukin 6. Proc Natl Acad Sci USA 1993; 90:100061-100065.
8. Ferguson MO, Aisen PJ. IL-1 and anti-inflammatory drugs modulate Aβ cytotoxicity in DC12 cells. Brain Res 1996; 723:231-234.
9. Graves AB, White E, Koepsell TD, Reifler BV, van Belle G, Larson EB. Acase control study of Alzheimer's disease. Ann Neurol 1990; 28:766-774.
10. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF. A case controlled study of Alzheimer's disease in Australia. Neurology 1990; 40:1698-1707.
11. Henderson AS, Jorm AF, Korten AE, Creaey H, McCusker E, Broe GA. Environmental risk factors for Alzheimer's disease: their relationship to age of onset and to familial or sporadic types. Psychol Med 1992; 22:429-436.
12. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin controlled study. Neurology 1994; 44:227-232.
13. The Canadian Study of Health and Aging. Risk factors for Alzheimer's disease in Canada. Neurology 1994; 44:2073-2080.
14. Mcgeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents are possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47:425-432.
15. Lucca U, Comelli M, Tettamanti M, Tiraboschi P, Spagnoli A. Non-steroidal anti-inflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994; 36(12):854-856.
16. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Non-steroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45(1):51-55.
17. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43(8):1609-1611.
18. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87(2):319-324.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: DSM-IV, 1994.
20. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psych 1984; 141:1356-1364.
21. Veroff AE, Cutler NR, Sramek JJ, Prior PL, Mickelson W, Hartmann JK. A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test Battery. J Geriatr Psychiatry Neurol 1991; 4(4):211-217.
22. Sainati SM, Ingram DM, Talwaker S, et al. Results of double-blind, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease (abstract). 6th International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy, Stockholm, Apr 5-8, 2000.
23. Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, Hourani J, Zolnouni P. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998; 97:244-250.
24. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC. Treatment of osteoarthritis with celcoxib, a cyclooxeganase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74(11):105-1095.
25. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group. JAMA 2002; 287(1):64-71.
26. Kivitz AJ, Moskowits RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, Geis GS. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001; 29(6):467-479.
27. Gimbel JS, Brugger A, Zhao W, Verburg KM, Geis GS. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001; 23(2):228-241.
28. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celcoxib versus diclofenac in the mangement of osteoarthritis of the knee. Scand J Rheumatol 2001; 30(1):11-18.
29. McGeer PL. Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 2000; 17(1):1-11.